The Polda Metro Jaya police are investigating a liquid leak that originated from Iran and was distributed to various locations across Europe and Indonesia. The liquid is reported to be primarily used for electronic cigarette liquids.
On June 12th, 2022, Jaya Kombes Mukti Juharsa, the director of pharmaceuticals at Metro, stated at a press conference that "these liquids are intended for use in electronic cigarettes.
Evidence suggests that the liquid spillage incident is the first case of its kind in Indonesia. Muty stated that these liquids pose a danger to society, particularly to young people.
The narcotics division of Jakarta's Metro Jaya Police have released information about the spread of a new type of drug that includes liquid e-cigarette substances.
According to Muti, on November 27th, the ChaYa Drug Administration of Borda Metro conducted a drug investigation using a liquid form of methamphetamine as a base. Evidence suggests that this liquid is a new type of drug. This new form is being used to produce MDMA (multimetal oxide) drugs or liquids.
The fluid is being transported from Iran to various parts of Europe. According to reports, the liquid originates from a new substance found in Indonesia.
2FIRSTS will continue to keep track of this topic and update the latest information on the "2FIRSTSAPP". Scan the QR code below to download the app.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
